

Mental Health Medication Advisory Committee Meeting
Meeting Minutes, Open Session
February 12, 2019 2:00pm – 4:30 p.m.

<p>MHMAC Open Session DXC Technology Capital Room 6511 Forbes Ave. Topeka, KS 6619</p>	<p>Committee Members Present: Vishal Adma, MD (Interim Chairperson) Rebecca Klingler, MD Charles Millhuff DO Holly Cobb, APRN Taylor Porter, MD Bradley Grinage, M.D. Karen Moeller, PharmD</p> <p>Committee Members Absent: Nicole Ellermeier, PharmD DeAnn Jenkins, M.D.</p> <p>KDHE/Contractor Staff Present: Lee A. Norman, M.D. Annette Grant, RPh., Victor Nguyen, PharmD Margaret O'Donnell, Transcriptionist</p> <p>MCO Representatives Present: Jennifer Murff, RPh. – United Healthcare Angie Zhou, PharmD – Sunflower Health Plan Alan Carter, PharmD – Aetna Better Health of Kansas</p> <p>DXC/HID Staff Present: Karen Kluczykowski, RPh. Kathy Kaesewurm, RN, BSN</p>	<p>Representatives: Scott Brunner, Keith Wisdom, Kim McBratney, Aetna; Larry Holland, KDHE; Roy Lindfield, Sunovion; Jeff Mussack, Rick Kegler, Otsuka; Tammy Carsteen, JA of KS</p> <p>*Illegible names on sign-in sheet were not included.</p>
--	---	---

	DISCUSSION
I. Call to Order A. Introduction B. Announcements	Call to Order: Dr. Adma called the meeting to order at 2:05 p.m. Announcements: Dr. Lee Norman, KDHE, Acting Secretary Victor Nguyen, PharmD, KDHE, Pharmacy Program Assistant Manager Alan Carter, PharmD, Aetna Better Health of Kansas, Pharmacy Director *Standard parking lot notice
II. Old Business A. Review and approval of August 14, 2018 Meeting Minutes	Committee Discussion: None.
II. Old Business B. Review and approval of November 13, 2018 Meeting Minutes	Committee Discussion: None. Decision and/or Action: Dr. Millhuff moved to approve the minutes (for both dates). Dr. Porter seconded the motion. The motion carried unanimously.
II. Old Business C. Data request results a. Mirtazapine or Trazadone - concurrent use with other antidepressants.	Clinical Public Comment: No requests were received. Background: Brought back to the Committee for requested clarification of previously approved criteria from multiple concurrent use of Mirtazapine and Trazadone due to operational challenges to see if there is a need for any additional PA criteria.

	<p>Committee Discussion: Data results not significant enough for a PA edit and backside monitoring for safety is sufficient rather than a front-side edit where there would be so many unnecessary PAs. State recommended doing a RDUR audit and if a patient falls in that criteria, a provider education letter would be necessary.</p>
<p>II. Old Business C. Data request results b. Patients over 65 taking antipsychotics who are not in the Long-Term care setting</p>	<p>Clinical Public Comment: No requests were received.</p> <p>Background: Additional data review of patients over 65 yrs. old who are not in the LTC setting.</p> <p>Committee Discussion: Data results showed the number of patients too low to do a PA edit. There was discussion about what diagnoses would lower that number and there was a request to look at dementia with behavioral disturbances, any kind of psychosis with severe aggression. There was discussion about starting with a provider education letter that will list the patient and situation it pertains to. Peer-to-peer discussion would address the safety on the backside.</p>
<p>II. Old Business D. Review of the Kansas version of the Texas Guidelines for Psychotropic Medication Utilization Parameters</p>	<p>Clinical Public Comment: No requests were received.</p> <p>Background: Workgroup's attempt to decrease over-utilization of psychotropic medications in children in foster care in Kansas. Proposing working co-jointly with MHMAC in having the medication parameters/guidelines used as educational purposes for providers. The goal is to have a document for prescribers in the State to refer to as a guideline.</p> <p>Committee Discussion: There was discussion about using the document as an educational tool as a starting point and after revisions and updates are made could be used as a guideline. There was a discussion about whether this document has been peer-reviewed or vetted by anyone other than the authors. Ms. Grant commented that the State made sure the FDA doses and Medicaid doses were correct. There was discussion about the Committee endorsing pages 1-5 and having them linked to the PA criteria that is already in place.</p>

	<p>Decision and/or Action: Dr. Millhuff moved to approve pages 1-5. Dr. Grinage seconded the motion. The motion carried unanimously.</p>
<p>III. New Business A. Prior Authorization Criteria 1. Antipsychotic Medications – Safe Use for All Ages</p>	<p>Clinical Public Comment: No requests were received.</p> <p>Background: Ms. Grant proposed adding Abilify MyCite® along with its corresponding dosing limits and a step-therapy. Rick Kegler with Otsuka spoke about the issue of efficacy.</p> <p>Committee Discussion: Added step-therapy criteria of must meet FDA label requirements for approved use, documented tolerance to aripiprazole tablets and not able to receive injections.</p> <p>Decision and/or Action: Dr. Moeller moved to approve as amended. Dr. Porter seconded the motion. The motion carried unanimously.</p>
IV. Open Public Comment	<p>Clinical Public Comment: None.</p>
	<p>Committee moved into closed session from 4pm to 4:20pm. Discussion only. Committee moved back to open session at 4:20pm.</p>
V. Adjourn	<p>Dr. Klingler moved to adjourn. Holly Cobb, APRN seconded the motion. The motion to adjourn was approved unanimously.</p> <p>The meeting adjourned at 4:23pm.</p>